Bli medlem
Bli medlem

Du är här

2016-01-11

Sanofi : Sanofi and Warp Drive Bio to Collaborate on the Development of Novel Oncology Therapies and Antibiotics Based on Proprietary Platforms

Sanofi and Warp Drive Bio to Collaborate on the Development of Novel Oncology
Therapies and Antibiotics Based on Proprietary Platforms

- New Collaboration to Provide Warp Drive Funding and Milestones in Excess of
$750 Million -

Paris, France - January 11, 2016 -
SanofiandWarp Drive Bio, a privately held biotechnology company using the
molecules and mechanisms of nature to discover and develop transformative
medicines, today announced that they have extended and reshaped their
existing collaboration utilizing Warp Drive's proprietary SMART(TM) (Small
Molecule Assisted Receptor Targeting) and Genome Mining platforms to discover
novel oncology therapeutics and antibiotics.

Sanofi, who has been a major investor and strategic partner since Warp Drive's
inception in 2012, and Warp Drive have entered into a research collaboration
and exclusive license focused on the development of drugs targeting important
human oncogenes including RAS, which has one of the highest mutation rates in
cancer - and new antibiotics targeting Gram-negative bacteria. Warp Drive Bio
retains the rights to deploy its platforms to pursue discovery and
development against all other targets, both alone and in collaboration with
other companies.

The collaboration is an outgrowth of Sanofi'sSunriseinitiative, a strategic
partnership model that seeks to invest in early stage opportunities that
align with Sanofi's expert development and commercialization abilities.

"Our partnership with Warp Drive is a perfect example of open innovation which
allows Sanofi to collaborate with innovative companies and combine unique
areas of expertise to advance drug development in a meaningful way",
said Elias Zerhouni, M.D., President, Sanofi, Global R&D."This is an exciting
collaboration for Sanofi as it could yield potentially
lifesaving oncology and antibiotic therapies for patients by utilizing
cutting-edge technology platforms."

"This reshaped alliance enables joint and independent product development by
Warp Drive, an important step in our evolution as we advance a therapeutic
pipeline using our proprietary platforms,"
said Laurence Reid, Ph.D., Chief Executive Officer, Warp Drive Bio."Since our
inception, Sanofi has been highly supportive of our progress and we
are very pleased to reshape our strategic collaboration to focus on novel
therapeutics in areas of great unmet need."

Under the terms of the Agreement, Warp Drive will lead the research
collaboration for a period of five years and Sanofi will receive worldwide
exclusive licenses to develop and commercialize the candidates discovered
during the research term.

Warp Drive is eligible to receive from Sanofi cumulative payments in excess of
$750 million across four successful collaboration programs, including an
equity investment by Sanofi, research, clinical, and regulatory milestones,
and research and development services.

The companies will initially focus on three defined oncology programs
targeting different mutants and states of the RAS oncogenic protein. Warp
Drive has the option to lead development of the therapeutic candidates from
post IND filing up to phase 2 clinical studies, with Sanofi leading
development through the filing of new drug applications. Sanofi will lead
global commercial activities on product(s) resulting from the collaboration
and Warp Drive has the option to co-commercialize oncology therapeutics in
the U.S. market. Sanofi will manage all ex-US commercial activities and Warp
Drive will receive commercial milestones and tiered royalties on product
sales.

The antibiotic collaboration will focus on the discovery and development of
novel Gram-negative therapeutics and Sanofi will lead all development
activities. Sanofi will be responsible for global commercialization of the
antibiotic products and will pay Warp Drive research, clinical, and
regulatory milestones, plus tiered royalties and commercial milestones based
on global sales.

A review of Warp Drive's SMART platform and its application to RAS and other
important disease targetswas discussed in a plenary sessionat the recent
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer
Therapeutics. Warp Drive believes that novel therapeutics targeting RAS will
represent a significant advance in the future of oncology drug development.
Moreover, creating a new modality for currently undruggable targets by
deploying the company's SMART platform has the potential to open up new
avenues for additional therapeutics in oncology and other important disease
areas.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi has core strengths
in diabetes solutions, human vaccines, innovative drugs, consumer healthcare,
emerging markets, animal health and Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).

About Warp Drive Bio

Warp Drive Bio is exploiting the molecules and mechanisms of nature to create
transformative medicines. The company operates on the core principle that
nature is the world's most powerful inventor of new drugs, unconstrained by
the mechanistic and synthetic limitations of traditional medicinal chemistry.
Warp Drive Bio is deploying its proprietary Genomic Mining and SMARTTM (Small
Molecule Assisted Receptor Targeting) platforms to discover novel medicines
that have the potential to make a significant difference in patients' lives.
The company was launched in 2012 through a strategic partnership with Sanofi
and with financing from Third Rock Ventures and Greylock Partners. For more
information, please visit www.warpdrivebio.com.

Sanofi Forward Looking Statements
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements
include projections and estimates and their underlying assumptions,
statements regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services, product
development and potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words "expects",
"anticipates", "believes", "intends", "estimates", "plans" and similar
expressions. Although Sanofi's management believes that the expectations
reflected in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or implied or
projected by, the forward-looking information and statements. These risks and
uncertainties include among other things, the uncertainties inherent in
research and development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or biological
application that may be filed for any such product candidates as well as
their decisions regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates, the absence
of guarantee that the product candidates if approved will be commercially
successful, the future approval and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth
opportunities, trends in exchange rates and prevailing interest rates, the
impact of cost containment initiatives and subsequent changes thereto, the
average number of shares outstanding as well as those discussed or identified
in the public filings with the SEC and the AMF made by Sanofi, including
those listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the
year ended December 31, 2014. Other than as required by applicable law,
Sanofi does not undertake any obligation to update or revise any
forward-looking information or statements.

---------------------------------------
------------------------------------------------------------------
| Contacts: Sanofi Investor Relations |
| |
| Sébastien Martel |
|Sanofi Corporate Media Relations Tel.: + 33 (0) 1 53 77 45 45 |
| ir@sanofi.com |
|Laurence Bollack |
|Tel. : +33 (0)1 53 77 46 46 |
|mr@sanofi.com |
| Sanofi Global R&D Communications |
| |
| |
|Amy BA, Ph.D. |
|Tel: +1 (617) 665-4851 |
|amy.ba@sanofi.com |
| Warp Drive Bio Media Relations |
| |
| |
|Dan Budwick |
|Pure Communications |
|973-271-6085 |
------------------------------------------------------------------
Press release (PDF)
http://hugin.info/152918/R/1977797/724187.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sanofi via Globenewswire

HUG#1977797

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.